New alpha therapy targets tough prostate cancer
Disease control
Ongoing
This early-stage study tests a new drug called AB001, which delivers a powerful radioactive particle directly to prostate cancer cells. It is for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose a…
Phase: PHASE1 • Sponsor: ARTBIO Inc. • Aim: Disease control
Last updated May 04, 2026 02:48 UTC